Journal article
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
British journal of cancer, Vol.121(5), pp.417-420
08/27/2019
DOI: 10.1038/s41416-019-0530-6
PMCID: PMC6738060
PMID: 31353364
Abstract
Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB-IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single >= 25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudoprogression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors.
Details
- Title: Subtitle
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
- Creators
- Jason Chesney - University of LouisvilleIgor Puzanov - Roswell Park Cancer InstituteFrances Collichio - University of North Carolina at Chapel HillMohammed M. Milhem - University of Iowa Hospitals and ClinicsAxel Hauschild - Christian-Albrechts-Universität zu KielLisa Chen - Amgen (United States)Anjali Sharma - Amgen (United States)Claus Garbe - University Children's Hospital TübingenParminder Singh - Mayo Clinic HospitalJanice M. Mehnert - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- Resource Type
- Journal article
- Publication Details
- British journal of cancer, Vol.121(5), pp.417-420
- DOI
- 10.1038/s41416-019-0530-6
- PMID
- 31353364
- PMCID
- PMC6738060
- NLM abbreviation
- Br J Cancer
- ISSN
- 0007-0920
- eISSN
- 1532-1827
- Publisher
- Springer Nature
- Number of pages
- 4
- Grant note
- Amgen Inc.; Amgen P30CA086862 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 08/27/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359771602771
Metrics
22 Record Views